Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms

Bioorg Med Chem. 2010 Jun 1;18(11):3999-4008. doi: 10.1016/j.bmc.2010.04.024. Epub 2010 Apr 18.


The tyrosine kinase Src and its close homolog Abl, both play important roles in chronic myelogenous leukemia (CML) progression and Imatinib resistance. No clinically approved inhibitors of the drug-resistant AblT315I exist to date. Here, we present a thorough kinetic analysis of two potent dual Src-Abl inhibitors towards wild type Src and Abl, and the AblT315I mutant. Our results show that the most potent compound BO1 shows only a modest loss of potency (fourfold) towards the AblT315I mutant in vitro and was an ATP-competitive inhibitor of wild type Abl but it acted as a non-competitive inhibitor in the case of AblT315I.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate
  • Benzamides
  • Drug Resistance, Neoplasm
  • Humans
  • Imatinib Mesylate
  • Kinetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Mutant Proteins / antagonists & inhibitors*
  • Mutation, Missense
  • Piperazines / pharmacology
  • Protein Kinase Inhibitors / pharmacology*
  • Proto-Oncogene Proteins c-abl / antagonists & inhibitors*
  • Pyrimidines / pharmacology
  • src-Family Kinases / antagonists & inhibitors*


  • Benzamides
  • Mutant Proteins
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Adenosine Triphosphate
  • Proto-Oncogene Proteins c-abl
  • src-Family Kinases